SEC Form 4 · accession 0000919574-18-005773
PAIN THERAPEUTICS INC · PTIE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
ARMISTICE CAPITAL, LLC
10% Owner
Armistice Capital Master Fund Ltd.
10% Owner
Steven Boyd
10% Owner
Period of report
Aug 16, 2018
Accepted (ET)
Aug 20, 2018 · 5:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001069530
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F1 | Aug 16, 2018 | S | 1,200,000 | $1.0185 | D | 2,220,000 | D | |
| Common StockF2 | Aug 16, 2018 | S$0 | 0 | $0.00 | D | 2,220,000 | I | See Footnote |
| Common StockF2 | Aug 16, 2018 | S$0 | 0 | $0.00 | D | 2,220,000 | I | See Footnote |
| Common StockF4,F1 | Aug 17, 2018 | S | 48,000 | $0.9517 | D | 2,172,000 | D | |
| Common StockF2 | Aug 17, 2018 | S$0 | 0 | $0.00 | D | 2,172,000 | I | See Footnote |
| Common StockF2 | Aug 17, 2018 | S$0 | 0 | $0.00 | D | 2,172,000 | I | See Footnote |
| Common StockF1 | Aug 20, 2018 | S | 8,000 | $0.9068 | D | 2,164,000 | D | |
| Common StockF2 | Aug 20, 2018 | S$0 | 0 | $0.00 | D | 2,164,000 | I | See Footnote |
| Common StockF2 | Aug 20, 2018 | S$0 | 0 | $0.00 | D | 2,164,000 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are directly owned by Armistice Capital Master Fund Ltd.
- F2The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3This constitutes the weighted average sale price. The prices range from $0.9851 to $1.0677. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This constitutes the weighted average sale price. The prices range from $0.9091 to $0.9998. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.